TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10580458
Drug: Rofecoxib (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5, 25, or 50 mg/d)
Study: 10580458
Drug: NSAIDs (ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ibuprofen, diclofenac, nabumetone)
Study: 7825523
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid supplementation (12 g fish oil)
Study: 2328299
Drug: Diltiazem conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem conventional tablet (2 x 30 mg)
Study: 2328299
Drug: Diltiazem slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem slow-release capsule (120 mg SR)
Study: 438650
Drug: Bile acid
Normalized name: Bile acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile acid mixture (cholic‐chenodeoxycholic 2:1, 20 mg/kg)
Study: 438650
Drug: Sitosterol-bile acid
Normalized name: sitosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitosterol-bile acid mixture (bile acid mixture plus sitosterols, 200 mg/kg)
Study: 15878048
Drug: Ecologically based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecologically based family therapy (EBFT)
Study: 25887789
Drug: Elective laparoscopic
Normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective laparoscopic appendectomy plus maintenance treatment (5‐ASA)
Study: 25887789
Drug: Maintenance 5‐ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance 5‐ASA treatment (no appendectomy)
Study: 19338149
Drug: Shugan Liangxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shugan Liangxue Compound (SLC)
Study: 2497647
Drug: 2.5 cm
Normalized name: NeuroMatrix, 2 mm IDx2.5 cm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 cm capsule (12 mg of levonorgestrel)
Study: 2497647
Drug: 4.0 cm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 cm capsule (21.6 mg of levonorgestrel)
Study: 7293937
Drug: Whole eggs
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole eggs (0.5 cup, approximately 500 mg cholesterol)
Study: 30602311
Drug: Topical spironolactone
Normalized name: spironolactone Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spironolactone
Study: 28880750
Drug: Aqua-Lymphatic Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua-Lymphatic Therapy (ALT), group sessions twice a week for 6 weeks
Study: 28880750
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, group sessions twice a week for 6 weeks
Study: 25541155
Drug: Age >55,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age >55, maximum grade of PN during docetaxel treatment, persistent muscle and joint pain, stomatitis, fatigue
Study: 19122354
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg overnight dexamethasone suppression test
Study: 19122354
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg overnight dexamethasone suppression test
Study: 18082216
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin)
Study: 12364431
Drug: Oral Medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Medroxyprogesterone Acetate (MPA)
Study: 12364431
Drug: Oral Micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Micronized Progesterone (MP)
Study: 9250122
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg elemental Zn daily for 6 months)
Study: 8099118
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment based upon weight reduction and recommendations about a low alcohol intake
Study: 8099118
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment using a stepped-care approach with atenolol as the first-choice drug
Study: 3828192
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg i.v. prochlorperazine
Study: 3828192
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg i.v. prochlorperazine
Study: 11333010
Drug: Telmisartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (angiotensin II receptor antagonist)
Study: 30648598
Drug: Oat noodles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat noodles (100 g, replacing one or two meals/day for 10 weeks)
Study: 30145267
Drug: Standard rehabilitative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitative care (physical and occupational therapy and psychoeducation)
Study: 30145267
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and integrative health therapies (chiropractic, acupuncture, yoga and psychoeducation)
Study: 30145267
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment (if initial treatment is not effective)
Study: 30145267
Drug: First-stage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-stage treatment plus the alternative treatment (if initial treatment is not effective)
Study: 23038682
Drug: 7.47 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.47 g of intravenous methylprednisolone
Study: 23038682
Drug: 4.98 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.98 g of intravenous methylprednisolone
Study: 23038682
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g of intravenous methylprednisolone
Study: 17376268
Drug: Thymosin-alpha1 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin-alpha1 1.6 mg by subcutaneous injection twice daily for 1 week
Study: 17376268
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (broad-spectrum antibiotics only)
Study: 11905433
Drug: Alcohol (social
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (social dose)
Study: 2149688
Drug: Octreotide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (400 micrograms per day via continuous subcutaneous infusion)
Study: 6992856
Drug: Topical oxytetracycline
Normalized name: oxytetracycline Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxytetracycline oily suspension, twice daily for 7 days each month for 12 months
Study: 6992856
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline 5 mg per kilogram of body weight, once a month for 12 months
Study: 6992856
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received vitamin pills once a month
Study: 28553847
Drug: Ezetimibe (EZE)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (EZE) 10 mg/day co-administered with atorvastatin 20 mg for 16 weeks
Study: 28553847
Drug: Atorvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin monotherapy (20 mg for 16 weeks)
Study: 22940818
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) at doses of 6,000 or 12,000 IU administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Study: 22940818
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously within 6 hours after successful percutaneous coronary intervention (PCI)
Study: 19237568
Drug: MF59‐H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59‐H5N1 vaccine
Study: 19237568
Drug: Plain H5N1
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain H5N1 vaccine
Study: 17890472
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin
Study: 15890830
Drug: Unrestricted oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrestricted oral carbohydrate intake during labor
Study: 7524159
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (Taxol) 3-hour infusion without G-CSF
Study: 7524159
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (Taxol) 3-hour infusion with G-CSF
Study: 7524159
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (Taxol) 3-hour infusion
Study: 2895993
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium (15 to 60 mg/d)
Study: 2895993
Drug: Buspirone hydrochloride
Normalized name: Buspirone Hydrochloride
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone hydrochloride (10 to 40 mg/d)
Study: 31628668
Drug: Rifampicin 150
Normalized name: Rifampicin 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 150 mg
Study: 31628668
Drug: Rifampicin 300
Normalized name: Rifampicin 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 300 mg
Study: 973984
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg
Study: 31628668
Drug: Probe drug
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probe drug cocktail (atorvastatin, pitavastatin, rosuvastatin, valsartan)
Study: 31078149
Drug: Humic acid
Normalized name: humic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humic acid (100 mg.L‐1) with CuO nanoparticles (various concentrations)
Study: 31078149
Drug: Humic acid
Normalized name: humic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humic acid (100 mg.L‐1)
Study: 28327379
Drug: Computer tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer tablet
Study: 25288262
Drug: 2,790-nm resurfacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,790-nm resurfacing laser (double pass treatment at fluences less than or equal to 2.5 mJ with 10% overlap)
Study: 25288262
Drug: 2,790-nm resurfacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,790-nm resurfacing laser (one pass treatment at fluences greater than or equal to 3.0 mJ with 10% overlap)
Study: 23982575
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor physical therapy (PFPT) 2 weeks preoperatively and 2, 4, 6, 8, and 12 weeks postoperatively
Study: 21762357
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg/Amlodipine 5 mg (T40/A5)
Study: 24391142
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/Amlodipine 5 mg (T80/A5)
Study: 22853848
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg (A5)
Study: 22853848
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg (A10)
Study: 19092234
Drug: NPPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPPV plus usual dosage of oxygen
Study: 19092234
Drug: Usual dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dosage of oxygen
Study: 14574511
Drug: Scintigraphic evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scintigraphic evaluation using 5, 10, 15, and 20 ml of water containing 0.5 mCi technetium‐99m labelled sulphur colloid
Study: 8784560
Drug: Prior antibiotic
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior antibiotic treatment
Study: 1472394
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with initial cholesterol level of 6.50 mmol l‐1 or greater.
Study: 1472394
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group with initial cholesterol level of less than 5.20 mmol l‐1.
Study: 19701237
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg clarithromycin tablets twice a day for 4 days
Study: 19701237
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 4 days
Study: 17590156
Drug: Sub-antimicrobial dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-antimicrobial dose doxycycline (SDD)
Study: 6704545
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with weekly cytosine arabinoside and 6‐thioguanine alone (69 patients)
Study: 6704545
Drug: Two courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two courses of reduced doses of DAT 1 month apart followed by the same maintenance program (77 patients)
Study: 26752653
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose clazosentan (15 mg/h)
Study: 22835570
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) applied twice on the cervical erosion with a 1-week interval
Study: 8911108
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (VIMP) - vincristine, carboplatin, ifosfamide, mesna
Study: 8911108
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (CDE) - cyclophosphamide, doxorubicin, etoposide
Study: 1651434
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (one injection daily)
Study: 1651434
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low molecular weight heparin + dihydroergotamine (one injection daily)
Study: 1651434
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (3 applications of 5000 IU per day)
Study: 1651434
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Low molecular weight heparin alone)
Study: 1651434
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Combination treatment)
Study: 11720639
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Unfractionated heparin)
Study: 26541888
Drug: Encapsulated ileal-release
Normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated ileal-release glutamine (6.0 g)
Study: 23661494
Drug: 8-week preoperative
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week preoperative neuromuscular supervised exercise programme delivered twice a week for 1 hour as adjunct treatment to standard arthroplasty procedure
Study: 21110409
Drug: High-dosage (HD)
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage (HD) medical exercise therapy
Study: 21110409
Drug: Low-dosage (LD)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage (LD) exercise therapy
Study: 17956016
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 200 g twice-daily (b.i.d.)
Study: 17956016
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 200 g once-daily (q.d.)
Study: 17956016
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg three times daily (t.i.d.)
Study: 15875135
Drug: N2O administration
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N2O administration during washout of sevoflurane
Study: 12584874
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (NTP; n = 27)
Study: 12584874
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR plus nicotine patch (B + NTP; n = 61)
Study: 7978436
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg triazolam orally (Group 1)
Study: 7978436
Drug: 75 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 micrograms oral clonidine (Group 2)
Study: 7978436
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms oral clonidine (Group 3)
Study: 7978436
Drug: 300 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms oral clonidine (Group 4)
Study: 4407085
Drug: Intravenous dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextran 70
Study: 4407085
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Subcutaneous heparin and Intravenous dextran 70)
Study: 31449685
Drug: No concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No concomitant antiplatelet therapy (Control group)
Study: 28534153
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (Bevacizumab monotherapy and Bevacizumab plus carboplatin)
Study: 23416308
Drug: GS-9620 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9620 (0.3, 1, 2, 4, 6, 8 or 12 mg)
Study: 23416308
Drug: GS-9620 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9620 (8 or 12 mg)
Study: 23416308
Drug: GS-9620 (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9620 (≥ 2 mg)
Study: 21135022
Drug: ABT‐874 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 200 mg every other week (EOW)
Study: 21135022
Drug: ABT‐874 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐874 200 mg every week (EW)
Study: 3461725
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg + codeine 16 mg + caffeine 30 mg
Study: 31886591
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention (two consultations with a pharmacist 1-2 and 3-5 weeks after filling the prescription)
Study: 29437940
Drug: Standard LTBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard LTBI treatment plus two-way weekly text messaging
Study: 29437940
Drug: Standard LTBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard LTBI treatment
Study: 21912072
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg/day for 6 months)
Study: 17449579
Drug: Vitamins (folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins (folate 1 mg, vitamin B‐12 500 microg, vitamin B‐6 10 mg)
Study: 8083788
Drug: Saline group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline group, irrigation with 2 cc of physiologic saline
Study: 8083788
Drug: Tetracycline group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline group, irrigation with 2 cc of aqueous tetracycline hydrochloride, 50 mg/ml (5%)
Study: 8083788
Drug: Chlorhexidine group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine group, irrigation with 2 cc 0.12% chlorhexidine
Study: 2686071
Drug: Nifedipine (NF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NF) administered regularly for 2 months
Study: 2686071
Drug: Nifedipine (NF)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NF) withdrawal after 2 months of administration
Study: 31430755
Drug: CBT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT (Cognitive Behaviour Therapy)
Study: 29197203
Drug: Pharmacotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy and exercise
Study: 16938144
Drug: Extended cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended cognitive behaviour therapy (CBT) with or without behaviour strategies
Study: 15340532
Drug: Sequential antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential antiviral group (thymosin alpha1 1.6 mg, subcutaneous injection, 2 times/week for 8 weeks; interferon 500 MU, muscle injection, every other day for 6 months; lamivudine 100 mg/day after HBeAg seroconversion or interferon withdrawal for more than 18 months)
Study: 15340532
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (interferon and thymosin alpha1 simultaneously for 6 months)
Study: 15340532
Drug: Lamivudine group
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine group (more than 18 months treatment with lamivudine)
Study: 9598254
Drug: 0.3 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg.kg‐1 mivacurium
Study: 7834990
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion at 10 ng min‐1 kg‐1
Study: 7834990
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion at 2 ng min‐1 kg‐1
Study: 7834990
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion at 5 ng min‐1 kg‐1